We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Study Shows Why Leukemia Returns in Some Children
News

Study Shows Why Leukemia Returns in Some Children

Study Shows Why Leukemia Returns in Some Children
News

Study Shows Why Leukemia Returns in Some Children

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Study Shows Why Leukemia Returns in Some Children"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The researchers found that about 20 percent of children with T-cell acute lymphoblastic leukemia (T-ALL) who experience a relapse harbor mutations that activate NT5C2, an enzyme that inactivates an important chemotherapy drug, 6-mercaptopurine (6-MP).

The discovery may soon lead to improved treatment for patients. “The most immediate thing to do now is to develop diagnostic tools,” said Ferrando, professor of Pediatrics and of Pathology & Cell Biology in the Herbert Irving Comprehensive Cancer Center.

“With diagnostic tools, we could monitor for this mutation and if we see it, these patients should probably receive a different drug.”

About one in five children with T-ALL will suffer a relapse, and despite intensive chemotherapy, most of these children will die from the disease.

Based on his findings, Ferrando said relapsed patients with the mutated enzyme could be switched to a new drug, nelarabine, that’s very similar to 6-MP. The researchers found that even though the two drugs act similarly, they are different chemically, and nelarabine is not affected by the mutated enzyme.

Full findings of the research were published Feb. 3 in Nature Medicine.

The mutated enzyme also was discovered independently in a New York University study of patients with the B-cell form of ALL.

In a New York Genome Center article about both studies, the leader of the NYU study, William Carroll, MD, said

“I think for those of us who treat leukemia, it is a really dramatic finding. Access to [patient] samples and new next-generation sequencing [give us a way] to really understand the blueprint of relapse and to develop specific therapies. We can individualize treatment.”

Advertisement